Trial Profile
Tolerability and efficacy of switch from oral selegiline to orally disintegrating selegiline (Zelapar) in patients with Parkinson's disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Aug 2023
Price :
$35
*
At a glance
- Drugs Selegiline (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- 12 Mar 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 10 Apr 2008 New trial record.